Although not eligible for inclusion in this systematic review, because it did not report data for our target population separately, a phase 2 randomized study of patients with stage IIB–IV resected melanoma who received a vaccine comprising 12 MPs revealed that addition of GM-CSF did not enhance immunostimulation [77]. Here, CSF2 is linked to melanoma.